Tuesday, 15 September 2015

Iron Deficiency Anemia - Pipeline Review, H2 2015

Global Markets Direct's, 'Iron Deficiency Anemia - Pipeline Review, H2 2015', provides an overview of the Iron Deficiency Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Iron Deficiency Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Iron Deficiency Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


- The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Iron Deficiency Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Iron Deficiency Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Iron Deficiency Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Iron Deficiency Anemia Overview 6
Therapeutics Development 7
Pipeline Products for Iron Deficiency Anemia - Overview 7
Pipeline Products for Iron Deficiency Anemia - Comparative Analysis 8
Iron Deficiency Anemia - Therapeutics under Development by Companies 9
Iron Deficiency Anemia - Therapeutics under Investigation by Universities/Institutes 10
Iron Deficiency Anemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Iron Deficiency Anemia - Products under Development by Companies 14
Iron Deficiency Anemia - Products under Investigation by Universities/Institutes 15
Iron Deficiency Anemia - Companies Involved in Therapeutics Development 16
Panion & Bf Biotech Inc 16
Rockwell Medical, Inc. 17
Vifor Pharma AG 18
Iron Deficiency Anemia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ferric carboxymaltose - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ferric citrate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29

Request A Sample copy of This Report @ http://www.hexareports.com/sample/46625

ferric maltol - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ferric pyrophosphate citrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NSC-8679 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Proteins to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VIT-91 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Iron Deficiency Anemia - Recent Pipeline Updates 39
Iron Deficiency Anemia - Dormant Projects 53
Iron Deficiency Anemia - Product Development Milestones 54
Featured News & Press Releases 54
May 12, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Presentations at the 52nd ERA-EDTA Congress May 28-31, 2015 in London, UK 54
May 05, 2015: Rockwell Medical to Present at Bank of America Merrill Lynch 2015 Health Care Conference 54
Mar 26, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Poster Presentations at National Kidney Foundation Spring Clinical Meetings March 26-29, 2015 in Dallas, Texas 54
Jan 26, 2015: U.S. FDA Approves Rockwell's Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients 55
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch 56
Jan 09, 2015: Shield Therapeutics announces the publication of the AEGIS Feraccru Phase 3 pivotal trial manuscript in the Inflammatory Bowel Disease Journal 57
Jan 07, 2015: Rockwell Medical Announces Two Triferic Abstracts to be Presented at Annual Dialysis Conference Jan. 31 - Feb. 3, 2015 in New Orleans, Louisiana 57
Dec 15, 2014: American Regent's Injectafer (ferric carboxymaltose injection) Assigned J Code by Centers for Medicare & Medicaid Services 58
Dec 08, 2014: American Regent Announces Clinical Data Presentations at ASH 2014 59
Nov 11, 2014: Three clinical Presentations Highlight Novel Iron Replacement Drug Triferic at ASN 60
Appendix 61

About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Information:

Ryan Shaw

Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number

No comments:

Post a Comment